Immuneering (IMRX) announced a positive data update from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104, as well as plans to expand the Phase 2a trial to include three additional combination arms. Updated Data from Phase 2a Arm Evaluating IMM-1-104 with Modified Gemcitabine/nab-Paclitaxel in First Line Pancreatic Cancer as of December 5, 2024: As of December 5, 2024, three patients in the Phase 2a arm evaluating IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer achieved complete or partial responses for an overall response rate of 43% and disease control rate of 86%. Four patients remain on treatment. Benchmarks for gemcitabine/nab-paclitaxel alone in first-line pancreatic cancer patients were established by the Phase 3 MPACT study, which included 1 Complete Response out of 431 patients, a 23% Overall Response Rate, and a 48% Disease Control Rate.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering launches Pancreatic Cancer Advisory Board
- Immuneering to present data from Phase 2a trial of IMM-1-104 in early January
- Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
- Immuneering granted FDA Fast Track designation for IMM-1-104
- Immuneering Corp. Reports Q3 Loss, Highlights Progress